Pluristem Therapeutics Inc. (NASDAQ:PSTI – Get Rating) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totalling 584,400 shares, a drop of 23.7% from the March 15th total of 765,900 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is currently 0.4 days.
In other Pluristem Therapeutics news, Director Zami Aberman bought 80,616 shares of Pluristem Therapeutics stock in a transaction dated Thursday, February 10th. The stock was purchased at an average price of $1.80 per share, for a total transaction of $145,108.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Pluristem Therapeutics by 100.0% in the 3rd quarter. BlackRock Inc. now owns 13,357 shares of the biotechnology company’s stock worth $36,000 after buying an additional 6,680 shares in the last quarter. Two Sigma Securities LLC bought a new stake in shares of Pluristem Therapeutics in the 3rd quarter worth approximately $29,000. Geode Capital Management LLC lifted its holdings in shares of Pluristem Therapeutics by 98.3% in the 3rd quarter. Geode Capital Management LLC now owns 25,169 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 12,479 shares during the last quarter. TownSquare Capital LLC bought a new stake in shares of Pluristem Therapeutics in the 3rd quarter worth approximately $37,000. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of Pluristem Therapeutics by 67.6% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 42,350 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 17,079 shares during the last quarter. 19.25% of the stock is owned by institutional investors and hedge funds.
Pluristem Therapeutics (NASDAQ:PSTI – Get Rating) last released its quarterly earnings results on Monday, February 7th. The biotechnology company reported ($0.34) EPS for the quarter. On average, analysts predict that Pluristem Therapeutics will post -1.86 EPS for the current fiscal year.
Several equities analysts recently commented on the stock. Zacks Investment Research cut shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 12th. StockNews.com initiated coverage on shares of Pluristem Therapeutics in a research note on Thursday, March 31st. They set a “hold” rating for the company.
Pluristem Therapeutics Company Profile (Get Rating)
Pluristem Therapeutics Inc operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
- Get a free copy of the StockNews.com research report on Pluristem Therapeutics (PSTI)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.